Oridonin

別名：NSC-250682, Isodonol, Rubescenin

製品コード：S2335 純度：99.99%

Oridonin, a diterpenoid purified from Rabdosia rubescens, is a traditional agent with antitumor, anti-bacterial and anti-inflammatory effects. Oridonin inhibits AKT1 and AKT2 kinase activity with IC50 of 8.4 μM and 8.9 μM, respectively.

CAS No. 28957-04-2

サイズ	価格(税別)	在庫状況
10mM (1mL in DMSO)	JPY 29500	国内在庫あり
10mg	JPY 22000	国内在庫あり

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（22）

カスタマーフィードバック1例

製品安全説明書

現在のバッチを見る：純度： 99.99%

99.99

Oridonin関連製品

関連ターゲット	Akt1 Akt2 Akt3	もっと見る
関連製品	MK-2206 2HCl Perifosine SC79 Capivasertib (AZD5363) GSK690693 Ipatasertib (GDC-0068) Triciribine (API-2) CCT128930 Afuresertib (GSK2110183) A-674563 HCl AT7867 Akti-1/2 PHT-427 TIC10 (ONC201) Miransertib (ARQ 092) HCl AT13148 Uprosertib (GSK2141795) Miransertib (ARQ-092) SC66 Deguelin ML-9 HCl	もっと見る
関連化合物ライブラリー	Kinase Inhibitor Library PI3K/Akt Inhibitor Library Apoptosis Compound Library Cell Cycle compound library NF-κB Signaling Compound Library	もっと見る

シグナル伝達経路

Aktシグナル伝達経路

Akt阻害剤の選択性比較

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	活性情報	PMID
HCT116	Cell cycle arrest assay	3 uM	24 hrs	Induction in cell cycle arrest in human HCT116 cells assessed as inhibition in cyclin A protein expression level at 3 uM incubated for 24 hrs by Western blot analysis	30981113
HCT116	Cell cycle arrest assay	3 uM	24 hrs	Induction in cell cycle arrest in human HCT116 cells assessed as inhibition in cyclin B1 protein expression level at 3 uM incubated for 24 hrs by Western blot analysis	30981113
HCT116	Apoptotic assay	1 uM	24 hrs	Induction of apoptotic morphological change in human HCT116 cells assessed as loss of original morphology at 1 uM incubated for 24 hrs by haematoxylin-eosin staining based microscopic method	30981113
HCT116	Apoptotic assay	1 uM	24 hrs	Induction of apoptotic morphological change in human HCT116 cells assessed as formation of unstructured state at 1 uM incubated for 24 hrs by haematoxylin-eosin staining based microscopic method	30981113
HCT116	Apoptotic assay	1 uM	24 hrs	Induction of apoptotic morphological change in human HCT116 cells assessed as formation of volume swelling at 1 uM incubated for 24 hrs by haematoxylin-eosin staining based microscopic method	30981113
HCT116	Apoptotic assay	1 uM	24 hrs	Induction of apoptotic morphological change in human HCT116 cells assessed as formation of condensed nuclei at 1 uM incubated for 24 hrs by haematoxylin-eosin staining based microscopic method	30981113
HCT116	Apoptotic assay	1 uM	24 hrs	Induction of apoptotic morphological change in human HCT116 cells assessed as cell lysis at 1 uM incubated for 24 hrs by haematoxylin-eosin staining based microscopic method	30981113
HCT116	Apoptotic assay	1 uM	24 hrs	Induction of apoptotic morphological change in human HCT116 cells assessed as membrane shrinkage at 1 uM incubated for 24 hrs by haematoxylin-eosin staining based microscopic method	30981113
HepG2	Function assay	0.1 to 1 uM	10 days	Inhibition of colony formation in human HepG2 cells at 0.1 to 1 uM incubated for 10 days by crystal violet staining based microscopic method	31200238
PLC/PRF/5	Function assay	0.001 to 1 uM	10 days	Inhibition of colony formation in human PLC/PRF/5 cells assessed as decrease in colony size at 0.001 to 1 uM incubated for 10 days by crystal violet staining based microscopic method	31200238
HL60	Cytotoxicity assay		48 hrs	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay, IC50=2.5μM	23819871
RAW264.7	Antiinflammatory assay		18 hrs	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by Griess method, IC50=5.2μM	23819871
K562	Antiproliferative assay		72 hrs	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay, IC50=4.33μM	28165738
Bel7402	Antiproliferative assay		72 hrs	Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay, IC50=5.41μM	28165738
MGC803	Antiproliferative assay		72 hrs	Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay, IC50=9.06μM	28165738
KB/CP4	Antiproliferative assay		48 hrs	Antiproliferative activity against human KB/CP4 cells after 48 hrs by MTT assay, IC50=10.8μM	28165738
KB-3-1	Antiproliferative assay		48 hrs	Antiproliferative activity against human KB-3-1 cells after 48 hrs by MTT assay, IC50=13.24μM	28165738
BEL7404/CP20	Antiproliferative assay		48 hrs	Antiproliferative activity against human BEL7404/CP20 cells after 48 hrs by MTT assay, IC50=17.17μM	28165738
MCF7	Antiproliferative assay		72 hrs	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay, IC50=17.89μM	28165738
Bel7404	Antiproliferative assay		48 hrs	Antiproliferative activity against human Bel7404 cells after 48 hrs by MTT assay, IC50=17.92μM	28165738
NCI-H460	Antiproliferative assay		48 hrs	Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay, IC50=20.51μM	28165738
NCI-H460/MX20	Antiproliferative assay		48 hrs	Antiproliferative activity against human NCI-H460/MX20 cells after 48 hrs by MTT assay, IC50=25.86μM	28165738
K562	Antiproliferative assay		72 hrs	Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50=4.64μM	30921757
SGC7901	Antiproliferative assay		72 hrs	Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50=7.13μM	30921757
Bel7402	Antiproliferative assay		72 hrs	Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50=7.85μM	30921757
HL60	Antiproliferative assay		72 hrs	Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50=9.46μM	30921757
PC3	Antiproliferative assay		72 hrs	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50=10.07μM	30921757
A549	Antiproliferative assay		72 hrs	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50=18.15μM	30921757
L02	Cytotoxicity assay		72 hrs	Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50=19.53μM	30921757
HCT116	Antiproliferative assay		48 hrs	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay, IC50=6.84μM	30981113
L02	Cytotoxicity assay		48 hrs	Cytotoxicity in human L02 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay, IC50=6.97μM	30981113
Bel7402	Antiproliferative assay		48 hrs	Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay, IC50=9.59μM	30981113
MCF7	Antiproliferative assay		48 hrs	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay, IC50=17.56μM	30981113
MDA-MB-231	Antiproliferative assay		48 hrs	Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay, EC50=29.4μM	30981113
PLC/PRF/5	Antiproliferative assay		72 hrs	Antiproliferative activity against human PLC/PRF/5 cells incubated for 72 hrs by CCK8 cells, IC50=7.41μM	31200238
HepG2	Antiproliferative assay		72 hrs	Antiproliferative activity against human HepG2 cells incubated for 72 hrs by CCK8 cells, IC50=8.12μM	31200238
RPMI8226	Antiproliferative assay		72 hrs	Antiproliferative activity against human RPMI8226 cells incubated for 72 hrs by CCK8 cells, IC50=9.25μM	31200238
LO2	Cytotoxicity assay		72 hrs	Cytotoxicity against human LO2 cells incubated for 72 hrs by CCK8 cells, IC50=17.47μM	31200238
A549	Antiproliferative assay		72 hrs	Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK8 cells, IC50=30.4μM	31200238
K562	Antiproliferative assay		72 hrs	Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50=4.79μM	31202992
SGC7901	Antiproliferative assay		72 hrs	Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50=7.87μM	31202992
Bel7402	Antiproliferative assay		72 hrs	Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50=8.31μM	31202992
A549	Antiproliferative assay		72 hrs	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50=17.8μM	31202992
L02	Cytotoxicity assay		72 hrs	Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50=18.68μM	31202992
TE1	Antiproliferative assay		72 hrs	Antiproliferative activity against human TE1 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay, IC50=12.73μM	31494472
A549	Antiproliferative assay		72 hrs	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay, IC50=13.45μM	31494472
MGC803	Antiproliferative assay		72 hrs	Antiproliferative activity against human MGC803 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay, IC50=14.13μM	31494472
MCF7	Antiproliferative assay		72 hrs	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay, IC50=21.97μM	31494472
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明

Targets

Akt1 ^[5] (Cell-free assay)	Akt2 ^[5] (Cell-free assay)
8.4 μM	8.9 μM

In Vitro
In vitro	Oridonin effectively inhibites the proliferation of a wide variety of cancer cells including those from prostate (LNCaP, DU145, PC3), breast (MCF-7, MDA-MB231), non-small cell lung (NSCL) (NCI-H520, NCI-H460, NCI-H1299) cancers, acute promyelocytic leukemia (NB4), and glioblastoma multiforme (U118, U138) with ED50s ranging from 1.8 to 7.5 μg/ml. ^[1] The antitumor activities of Oridonin may due to its inhibitory effects on NF-kappaB and MAPKs signal pathways. ^[2] ^[3]
実験結果図	Methods	Biomarkers	結果図	PMID
	Western blot	BCR-ABL / Myc p-AMPK / AMPK / Glut1 / LC3		28128329
	Immunofluorescence	HSF1 p65		28128329
	Growth inhibition assay	Cell viability		26496199

In Vivo
In Vivo	LD50: Mice 35-40mg/kg. ^[4]

参考
[1] Ikezoe T, et al. Int J Oncol, 2003, 23(4), 1187-1193. [2] Ikezoe T, et al. Mol Cancer Ther, 2005, 4(4), 578-586. [3] Cui Q, et al. J Pharmacol Sci, 2007, 105(4), 317-325. [4] E Fujita, et al. Experientia . 1976 Feb 15;32(2):203-6. [5] Mengqiu Song, et al. Mol Cancer Ther. 2018 Jul;17(7):1540-1553. + 展開

参考

+ 展開

化学情報

分子量	364.43	化学式	C₂₀H₂₈O₆
CAS No.	28957-04-2	SDF	Download Oridonin SDFをダウンロードする
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1个月-20°Cin solvent

In vitro
Batch:

DMSO : 72 mg/mL ( (197.56 mM)；吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Ethanol : 34 mg/mL

Water : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):